Abstract
Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
Keywords: Proteasome inhibitor, bortezomib, adverse effect, resistance.
Current Pharmaceutical Design
Title:Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Volume: 19 Issue: 18
Author(s): Biyin Cao, Jie Li and Xinliang Mao
Affiliation:
Keywords: Proteasome inhibitor, bortezomib, adverse effect, resistance.
Abstract: Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
Export Options
About this article
Cite this article as:
Cao Biyin, Li Jie and Mao Xinliang, Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/ 10.2174/13816128113199990338
DOI https://dx.doi.org/ 10.2174/13816128113199990338 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Subject Index To Volume 2
Current Drug Targets miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design Expression of P-gp, MRP, LRP, GST-π and TopoIIα and Acquired Resistance to Cisplatin in Human Lung Adenocarcinoma Cells
Letters in Drug Design & Discovery Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology New Generation of Liposomes Called Archaeosomes Based on Natural or Synthetic Archaeal Lipids as Innovative Formulations for Drug Delivery
Recent Patents on Drug Delivery & Formulation Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity
Current Drug Metabolism Synthetic Approaches to Functionalized Lipids for Protein Monolayer Crystallizations
Current Organic Chemistry Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy Radiologic Findings of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry